Category Archives: Global News Feed

Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of Directors Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of Directors

Excerpt from:
Kane Biotech Strengthens Board with Biotech Executive

TAMPA, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced its research partner, Aimia Pet HealthCo. Inc. (APH), has signed a memorandum of understanding (MOU) with KGK Science Inc. (KGK) for the development of a GLP1 supplement for pets.

See the original post:
Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement...

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.

Read more here:
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

COLOGNE, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has expanded its European footprint across the Czech Republic through a new export and distribution partnership with Cansativa Group. The new strategic partnership broadens Tilray Medical’s distribution of EU-GMP certified medical cannabis products across pharmacies and hospitals to support medical cannabis patient care.

Continue reading here:
Tilray Medical Expands Commercial Footprint in Europe and Broadens Distribution Across the Czech Republic

Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 2,942,358 titled, “Compositions for the Treatment of Autodigestion.” This key patent covers the composition of LB1148, the Company’s broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal damage, until 2035.

See the rest here:
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

Read the original here:
Virbac : Declaration of the number of shares and voting rights 03/2023